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ABSTRACT
ObjectiveToinvestigatetheassociationbetweengenus β
human papillomaviruses and the incidence of non-
melanocytic skin cancer in the general population.
Design Population based case-control study.
Setting New Hampshire, USA.
Participants2366skincancercasesandcontrolsfromthe
general population aged 25 to 74 years (663 squamous
cell carcinoma, 898 basal cell carcinoma, 805 controls),
withplasmasamplestestedforL1antibodiesto16genus
β human papillomaviruses by multiplex serology.
Main outcome measures Odds ratios for squamous cell
carcinoma and basal cell carcinoma associated with
seropositivity to β human papillomaviruses.
Results Squamous cell carcinoma, but not basal cell
carcinoma, cases had a higher prevalence of each of the
individual β human papillomaviruses assayed compared
with controls. The odds ratios for squamous cell
carcinoma increased with the number of β types positive
(odds ratio for one type positive 0.99 (95% confidence
interval 0.74 to 1.33); two to three types positive 1.44
(1.03 to 2.01); four to eight types positive 1.51 (1.03 to
2.20); more than eight types positive 1.71 (1.12 to 2.62);
P for trend (categorical)<0.001; P for trend (continuous)
=0.003). With limited statistical power, the association
was stronger among long term users of systemic
glucocorticoids (odds ratio 3.21, 1.22 to 8.44) than
among non-users (1.23, 0.97 to 1.55).
Conclusions These findings support a relation between
genus β human papillomavirus infection and the
incidence of squamous cell carcinoma of the skin in the
general population, as well as potential enhancement of
risk by immunosuppression.
INTRODUCTION
Inmanyregionsoftheworld,cancersarisingfromker-
atinocytes or their precursors (such as basal cell carci-
noma and squamous cell carcinoma) comprise the
most common malignancies, and the incidence rates
may be increasing rapidly.
1 As these often occur near
vital structures (such as the eye, nose, and ears), they
can cause considerable disfigurement and even death
in certain subgroups of the population, such as immu-
nosuppressed people.
1 Although ultraviolet radiation
is the main established risk factor, exposure to this has
not been easy to target for prevention or treatment.
Human papillomavirus infection is hypothesised to
playaroleinthepathogenesisofnon-melanocyticskin
cancer; if this is true, it would have important clinical
and public health implications. Papillomaviruses are
epitheliotropic, non-enveloped, double stranded
DNA viruses, of which more than 100 different types
havebeenidentified.
2Genusβpapillomaviruses,nota-
bly human papillomaviruses 5 and 8, were first identi-
fied in non-melanocytic skin cancers of patients with
epidermodysplasia verruciformis, a rare genetic disor-
dercharacterisedbydefectivecellmediatedimmunity,
manifesting diffuse warty and malignant skin lesions.
The International Agency for Research on Cancer’s
2007 monograph on human papillomaviruses recog-
nisedhuman papillomaviruses 5 and 8 as being“carci-
nogenic to patients with epidermodysplasia
verruciformis” but with limited evidence for carcino-
genicity in the general population.
3 A higher preva-
lence of antibodies to β human papillomavirus has
been detected among cases of squamous cell carci-
noma than controls in largely clinic based studies
with inadequate statistical power. Few population
based studies of these malignancies exist, partly
because they are typically excluded from cancer
registries.
4-11 Given the growing burden of non-
melanocytic skin cancers on ageing populations and
on healthcare systems, determining whether these
malignancies have a viral component could have a
big impact on clinical care and prevention of disease.
We therefore sought to investigate the association
betweenseropositivityto16genusβhumanpapilloma-
viruses and specific subtypes of non-melanocytic skin
cancers as part of an expanded analysis of our popula-
tion based case-control study from New Hampshire,
USA.
12 Asa secondary aim, we exploredmodifications
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ultraviolet radiation and immunology related factors.
METHODS
Study population
Participants included those described in our earlier
report,
6 along with additional cases and controls
included in a more recent enrolment phase. Briefly,
to identify cases we enlisted the collaboration of der-
matologists and pathology laboratories throughout
New Hampshire and borderingregions.
13 We selected
all identifiedcasesof histologically confirmed incident
invasive squamous cell carcinoma and a random sam-
ple of histologically confirmed incident basal cell car-
cinomacases(forefficiency),diagnosedbetween1July
1993 and 30 June 1995 in the initial enrolment phase
and between 1 July 1997 and 31 March 2000 in the
second enrolment phase. The sample of basal cell car-
cinoma cases was drawn concomitantly with the squa-
mouscellcarcinomacases(ataratioofabouttwobasal
cell carcinoma to one squamous cell carcinoma cases
in the first phase and one to one in the second phase).
We selected these basal cell carcinoma cases to repre-
senttheentirediagnosisgroupforanatomicalsite,age,
and sex. Eligible patients included residents of New
Hampshire who, at the time of diagnosis, were aged
25 to 74 years, spoke English, and had a listed tele-
phone number. We excluded people with squamous
cell or basal cell carcinomas on genital sites. We iden-
tified 2517 potential participants. Of these, we con-
tacted and confirmed the eligibility of 2457 (98%), of
whom 2014 (82%) were interviewed (1143 basal cell
carcinoma and 871 squamous cell carcinoma cases).
We chose controls from among residents of New
Hampshire aged 25 to 74 years who were frequency
matchedonage(25-34,35-44,45-54,55-64,65-69,and
70-74 years) and sex to represent the combined distri-
bution of the squamous cell carcinoma and basal cell
carcinoma cases. We selected controls (roughly equal
innumbertothenumberofbasalcellcarcinomacases)
fromlistsofNewHampshireresidentsprovidedbythe
New Hampshire Department of Transportation (for
those less than 65 years old) and Center for Medicaid
and Medicare Services (for those aged 65 and older).
As with cases, we required controls to speak English
and to have a listed telephone number. For inter-
viewing purposes, we randomly assigned reference
dates to controls corresponding to the cases’ dates of
diagnosis. Of the 1527 potential controls, 1462 (96%)
were contacted and confirmed as eligible, and 1066
(73%) of those were interviewed.
Personal interview
All participants provided informed consent in accor-
dance with the Committee for the Protection of
Human Subjects at Dartmouth College. Study partici-
pants completed a structured personal interview,
usually at their homes. To minimise reporting bias, we
did not reveal the specific hypotheses of interest to
either the interviewer or the participant and did not
informtheinterviewersofthecase-controlstatusofpar-
ticipants. The interview included sociodemographic
information (level of education), use of tobacco, pro-
longed use of glucocorticoid drugs (for one month or
longer) and reasons for use, assessment of pigmentary
characteristics and nevi, and questions relating to skin
sensitivity to the sun after first exposure in the summer
(tendency to sunburn). To estimate sun exposure, we
asked about the amount of time spent outdoors on
work days, non-work days, and vacations, bothin sum-
mer and at other times of the year; history of sunbath-
ing; number of painful and blistering sunburns; and
lifetime residential history by using a standardised
instrument developed for a case-control study in
Australia.
1415
Beginning with cases diagnosed in 1997, we
requested cases’ diagnostic materials (slides and para-
ffinembeddedtumourtissue)fromtheoriginalpathol-
ogy laboratory or dermatopathologist for histological
verification by the study pathologist. The assessment
included documentation of solar keratoses (yes/no),
definedby the presenceofatypicalepithelialcellscon-
fined to the epidermis in adjacent skin tissue.
Human papillomavirus serology
Wecollectedavenousbloodsampleofapproximately
20-30 mlin heparinisedtubes.Bloodwasseparatedby
centrifugation at 3000 rpm for 20 minutes at 4°C, and
plasma, white blood cells, and red blood cells (washed
twice in saline) were aliquotedand stored separatelyat
−80°C until analysis. Each specimen was labelled with
a type code (plasma, red blood cells, buffy coat) and a
unique identifier that did not reveal the participant’s
case-control status.
We analysed plasma samples for antibodies to the
major capsid protein L1 of β human papillomavirus
types 5, 8, 9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 76, 92,
96,and107.Webasedourantibodydetectionapproach
on a glutathione S-transferase capture enzyme linked
immunosorbent assay (ELISA) method,
1617 in combi-
nation with fluorescent bead technology.
18 Using this
approach, full length viral proteins fused with an
N-terminal glutathione S-transferase domain were
expressed in Escherichia coli bacteria. Glutathione cross
linked to casein was coupled to fluorescence labelled
polystyrene beads (Luminex, Austin, TX), and glu-
tathione S-transferase fusion proteins were affinity pur-
ifiedonthebeadsdirectlyinaonestepprocedure.Bead
types ofdifferent colour and carryingdifferentantigens
weremixedandincubatedwithhumansera.Antibodies
bound to the beads by the viral antigens were stained
by biotinylated anti-human immunoglobulin and
streptavidin-R-phycoerythrin. Beads were analysed in
a Luminex analyser that identified the bead colour—
and thus the antigen carried by the bead—and anti-
bodies bound to viral antigens were quantified by the
median R-phycoerythrin fluorescence intensity of at
least 100 beads of the same internal colour. Standard
thresholdsforapositivemedianR-phycoerythrinfluor-
escenceintensityreactionwerederivedfromasurveyof
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19 A reanalysis of our
earlier data with these thresholds made no substantial
difference to the results (data not shown).
6
The study sera were analysed once on each of three
consecutive days. As a quality control measure, a sub-
set of 166 study sera supplemented with 21 sera with
known reactivity from a previous study were tested
each day.
20 Pearson correlation coefficients (R
2) for
the individual antigens ranged from 0.634 to 0.967
(median 0.849) for day 2 versus day 1 and from 0.544
to0.980(median0.903)forday3versusday1.Asaddi-
tional quality controls, a standard serum with a known
reactivity pattern to a subset of the antigens was ana-
lysedoneach96wellplate,andloadingofthedifferent
beads with antigens was monitored by a monoclonal
antibody against a peptide fused to the C-terminus of
all expressed antigens.
17
Statistical analysis
Primary analysis
Weexaminedtheoverallandsexspecificprevalenceof
β human papillomavirus antibody positivity according
to skin cancer risk factors. We then calculated the odds
ratios and 95% confidence intervals for squamous cell
carcinomaandbasalcellcarcinomaassociatedwithser-
opositivity to β human papillomavirus types (overall
and by individual types). On the basis of earlier
work,
61019 we examined seropositivity to multiple
types (1, 2-3, 4-8, and >8 β types positive compared
with seronegative to all β types) and calculated a P
value for trend based both on these categories and on
a continuous variable of the number of types positive.
We tested for deviation from linearity by adding poly-
nominals (for example, a quadratic term) to the models
and by examining the plot of a general additive model
with loess smoothing (S-Plus 8.0, TIBCO Software).
Additionally, we evaluated each genus β species: β1
(human papillomavirus 5, 8, 20, 24, and 36), β2( H P V
9, 15, 17, 23, 38, and 107), β3 (HPV 49, 75, and 76), β4
(HPV 92), and β5 (HPV 96).
2 In each of these analyses,
we used unconditional logistic regression, taking into
accountmultipleconfoundingfactors.
21Possiblecovari-
ates included age, level of education (less than college,
college, graduate/professional school), smoking status
(never, current, former), skin sensitivity to the sun
(severe sunburn with blistering, painful sunburn, mild
sunburn with some tanning, and tanning with no sun-
burn), lifetime number of painful sunburns (0, 1-2, ≥3),
andoralglucocorticoiduse(no,yes,andreasonforuse).
We classified cases accordingto their status as of the
date of their first skin cancer diagnosed during the
study period and controls as of their reference date.
Classification of participants according to this plan
results in relative risks estimates of incidence density
ratios.
22 As a sensitivity analysis, we did analyses
restricted to participants who had had no previous
skin cancers to assess whether the risk estimates dif-
fered from those obtained for all participants. Addi-
tionally, we did analyses of squamous cell carcinoma
excluding people who had a concomitant basal cell
carcinoma(n=58;6.7%ofcases).Allriskestimatesulti-
mately were adjusted for or stratified by age, sex, and
sun sensitivity, and additionally for cigarette smoking
for cases of squamous cellcarcinoma. No other factors
appreciably influenced the results. We designed our
study to ensure at least 80% power with an α of 0.05
to detect odds ratios smaller than 2. For example, with
an α of 0.05, 80% power, and an approximate sample
size of 670 squamous cell carcinoma cases (the smaller
casegroup)and810controls,ourminimumdetectable
odds ratio calculated using conservative prevalence
estimates (that is, lower than actually observed) was
1.4 for a prevalence of 20% for β human papilloma-
virus seropositivity and 1.6 for a prevalence of 10% of
multiple types positive.
Secondary analyses
We calculated the odds ratios for basal cell carcinoma
and squamous cell carcinoma tumours separately in
comparison with controls and by anatomical sites
with chronic sunlight exposure (head and neck) versus
other sites, as well as separately by specific site of
occurrence (for example, head and neck, upper
limbs, trunk, and lower limbs). We further examined
subgroups of squamous cell carcinoma tumours
according to the presence of adjacent actinic keratoses
(yes, no). We assessed the potential modifying effects
of exposure to ultraviolet light by examining odds
ratios stratified by skin reaction to the sun (both in the
original four categories and dichotomised) and by life-
time number of painful sunburns (0, 1-2, 3-9, ≥10). As
human papillomaviruses have been related largely to
skin cancers occurring in immunosuppressed popula-
tions, we further considered the possibility that any
associations might be stronger among people with a
historyofprolongeduseoforalglucocorticoidsforrea-
sons other than organ transplantation. In these strati-
fied analyses, we classified participants as users if they
reportedusingglucocorticoidsforonemonthorlonger
(yes, no) and excluded those who reported having had
an organ transplant.
RESULTS
Primary analysis
We obtained results on human papillomavirus serol-
ogy for 2366 cases and controls (663 squamous cell
carcinoma, 898 basal cell carcinoma, 805 controls)
from whom a plasma sample was collected (excluding
seven squamous cell carcinoma cases, two basal cell
carcinoma cases, and seven controls with insufficient
or unprocessed samples). We noted no appreciable
case-controldifferencesinthecharacteristicsofpeople
from whom we did not obtain serology data (data not
shown). Looking first at the prevalence of β human
papillomavirusantibodiesbyparticipants’characteris-
tics among controls, we found that men had a slightly
higher proportion of antibody positivity to β human
papillomaviruses than did women, but the difference
was not statistically significant (48% in men v 42% in
women; P=0.11) (table 1). We did not see trends in
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smoking status, skin sensitivity to the sun, or number
of painful sunburns (table 1).
Theoddsratiosforsquamouscellcarcinoma,butnot
basal cell carcinoma, were elevated for each of the β
humanpapillomavirustypes,andeachgenusβspecies
examined; positivity to at least one β human papillo-
mavirus type was associated with an overall odds ratio
of 0.97 (95% confidence interval 0.80 to 1.19) for basal
cell carcinoma and 1.30 (1.04 to 1.61) for squamous
cell carcinoma (table 2). We found a clear increasing
trend in risk of squamous cell carcinoma with increas-
ing number of β human papillomavirus types positive,
onthebasisofboththecategoricalvariables(oddsratio
for one type positive 0.99 (0.74 to 1.33); odds ratio for
two to three types positive 1.44 (1.03 to 2.01); odds
ratio for four to eight types positive 1.51 (1.03 to
2.20); odds ratio for more than eight types positive
1.71 (1.12 to 2.62); categorical P for trend<0.001) and
a continuous scale (P for trend=0.003) (table 2). The
addition of a quadratic term did not improve the fit of
the model, and the plot of the general additive model
did not suggest deviation from linearity (data not
shown). These results did not materially change when
werestrictedtheanalysistofirstskincancersortopeo-
ple with squamous cell carcinoma alone (without a
concomitant basal cell carcinoma) (data not shown).
Secondary analyses
Odds ratios for squamous cell carcinoma were slightly
higher among cases with histological evidence of acti-
nic keratoses (1.59, 1.03 to 2.44) than among those
Table 1 |Distribution of human papillomavirus seropositivity among control participants by age, education, smoking status, and sunlight related factors.
Values are numbers (percentages)*
Variable
Overall Men Women
Total Genus β positive Total Genus β positive Total Genus βpositive
Overall 805 369 (46) 493 237 (48) 312 132 (42)
Age (years):
2 5 - 3 4 5 1( 2 0 ) 2 1( 5 0 ) 3 0( 0 )
35-49 118 53 (45) 55 21 (38) 63 32 (51)
5 0 - 5 4 5 9 2 8( 4 7 ) 3 7 1 8( 4 9 ) 2 2 1 0( 4 5 )
5 5 - 5 9 9 6 4 1( 4 3 ) 5 1 2 4( 4 7 ) 4 5 1 7( 3 8 )
60-64 111 49 (44) 79 34 (43) 32 15 (47)
65-69 223 111 (50) 146 79 (54) 77 32 (42)
70-74 193 86 (45) 123 60 (49) 70 26 (37)
Education:
High school or technical school 376 170 (45) 224 108 (48) 152 62 (41)
College 262 124 (47) 159 79 (50) 103 45 (44)
Graduate or professional school 167 75 (45) 110 50 (45) 57 25 (44)
Smoking status:
Never 276 125 (45) 130 66 (51) 146 59 (40)
Former 399 186 (47) 279 133 (48) 120 53 (44)
Current 130 58 (45) 84 38 (45) 46 20 (43)
Skin sensitivity†:
Severe sunburn with blistering 43 19 (44) 21 10 (48) 22 9 (41)
Painful sunburn followed by peeling 198 84 (42) 123 50 (41) 75 34 (45)
Mild sunburn with some tanning 408 189 (46) 247 125 (51) 161 64 (40)
Tan without sunburn 154 77 (50) 100 52 (52) 54 25 (46)
Lifetime No of painful sunburns:
None 256 114 (45) 152 74 (49) 104 40 (38)
1-2 231 104 (45) 132 64 (48) 99 40 (40)
≥3 309 147 (48) 202 96 (48) 107 51 (48)
Glucocorticoid use:
No 737 336 (46) 462 222 (48) 275 114 (41)
Yes 43 18 (42) 18 5 (28) 25 13 (52)
Reason for glucocorticoid use:
Respiratory conditions and asthma 10 3 (30) 3 0 (0) 7 3 (43)
Musculoskeletal and connective tissue disease 16 7 (44) 8 3 (38) 8 4 (50)
Neoplasm/gastrointestinal disease 6 3 (50) 2 0 (0) 4 3 (75)
Allergy 3 2 (67) 0 0 (0) 3 2 (67)
Other/unknown 9 4 (44) 5 2 (40) 4 2 (50)
*Numbers may not sum to overall totals owing to missing data; two men had missing data for skin sensitivity, and seven men had missing data for number of sunburns; two women had
missing data for number of sunburns; these participants were excluded from further analyses.
†Defined as reaction to one hour of sun exposure first time in summer.
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detected a stronger association between human papil-
lomavirus and squamous cell carcinoma among those
with a sun sensitive phenotype (table 3). We did not,
however,findany notabledifferencesaccordingtothe
anatomicalsiteofthesquamouscellcarcinomatumour
(data not shown) and did not find evidence of an inter-
actionwithhistoryofsunburns.Notably,theoddsratio
forsquamouscellcarcinomawithβhumanpapilloma-
virus positivity was about three among participants
with a history of prolonged glucocorticoid use (3.21,
1.22 to 8.44) and closer to one among those without
such a history (1.23, 0.97 to 1.55) (table 3). As people
with a history of glucocorticoid use may also have
takenotherimmunosuppressivedrugs(suchasmetho-
trexate), we restricted the analysis to conditions pri-
marily treated with glucocorticoids alone (for
example, asthma and allergies), and the odds ratio
remained higher in glucocorticoid users than in non-
users (odds ratio 1.91). However, none of the noted
differences in the strata specific odds ratios achieved
statistical significance.
DISCUSSION
Using a multiplex serological assay,
18 we tested for a
wide range of β human papillomaviruses in plasma
samples collected as part of a large population based
case-control study.Wedetectedanexcessriskofsqua-
mouscellcarcinomaassociatedwithallβhumanpapil-
lomaviruses examined and a clear increasing trend in
risk with increasing number of β types to which a per-
son tested positive. We further examined factors that a
priori might have been expected to modify associa-
tions. In these analyses, the association between squa-
mous cell carcinoma and β human papillomavirus
positivity was distinctly stronger among people with a
reported history of systemic glucocorticoid use.
Strengths and limitations of study
Our study included a large number of cases of histolo-
gically confirmed, invasive, incident squamous cell
carcinomathatwereidentifiedthroughanactivepopu-
lation based surveillance process involving dermatol-
ogists, dermatopathologists, and pathologists, as well
Table 2 |Odds ratios for basal cell carcinoma and squamous cell carcinoma with human papillomavirus (HPV) antibody
positivity
HPV serology results
Control—No (%)
(n=805)
Basal cell carcinoma (n=898) Squamous cell carcinoma (n=663)
No (%)
Adjusted odds ratio*
(95% CI) No (%)
Adjusted odds ratio*
(95% CI)
β HPV seronegative 436 (54.2) 502 (55.9) 1.00 (referent) 311 (46.9) 1.00 (referent)
β HPV seropositive 369 (45.8) 396 (44.1) 0.97 (0.80 to 1.19) 352 (53.1) 1.30 (1.04 to 1.61)
No of β HPV types positive:
1 155 (19.3) 180 (20.0) 1.03 (0.79 to 1.33) 118 (17.8) 0.99 (0.74 to 1.33)
2-3 93 (11.6) 98 (10.9) 0.97 (0.70 to 1.34) 101 (15.2) 1.44 (1.03 to 2.01)
4-8 71 (8.8) 71 (7.9) 0.92 (0.63 to 1.33) 73 (11.0) 1.51 (1.03 to 2.20)
>8 50 (6.2) 47 (5.2) 0.90 (0.58 to 1.38) 60 (9.1) 1.71 (1.12 to 2.62)
P for trend (categorical)=0.54; P for trend
(continuous)=0.55
Pfortrend(categorical)<0.001;Pfortrend
(continuous)=0.003
Specific β β HPV types
Any β1 192 (23.9) 198 (22.0) 0.95 (0.74 to 1.22) 212 (32.0) 1.52 (1.18 to 1.96)
5L1 41 (5.1) 42 (4.7) 1.03 (0.65 to 1.64) 43 (6.5) 1.45 (0.90 to 2.34)
8L1 123 (15.3) 120 (13.4) 0.91 (0.68 to 1.23) 127 (19.2) 1.45 (1.08 to 1.97)
20L1 122 (15.2) 113 (12.6) 0.83 (0.61 to 1.12) 131 (19.8) 1.45 (1.08 to 1.96)
24L1 81 (10.1) 75 (8.4) 0.92 (0.64 to 1.31) 84 (12.7) 1.53 (1.07 to 2.18)
36L1 58 (7.2) 55 (6.1) 0.89 (0.59 to 1.33) 59 (8.9) 1.49 (0.99 to 2.25)
Any β2 265 (32.9) 283 (31.5) 0.97 (0.77 to 1.21) 261 (39.4) 1.34 (1.06 to 1.7)
9L1 113 (14.0) 114 (12.7) 0.96 (0.70 to 1.3) 116 (17.5) 1.41 (1.03 to 1.92)
15L1 134 (16.6) 140 (15.6) 0.95 (0.72 to 1.27) 146 (22.0) 1.49 (1.11 to 1.99)
17L1 132 (16.4) 153 (17.0) 1.09 (0.82 to 1.43) 134 (20.2) 1.37 (1.02 to 1.83)
23L1 39 (4.8) 43 (4.8) 1.03 (0.65 to 1.65) 49 (7.4) 1.57 (0.98 to 2.52)
38L1 97 (12.0) 94 (10.5) 0.91 (0.66 to 1.26) 124 (18.7) 1.74 (1.27 to 2.4)
107L1 80 (9.9) 66 (7.3) 0.78 (0.54 to 1.13) 75 (11.3) 1.40 (0.97 to 2.02)
Any β3 136 (16.9) 138 (15.4) 0.97 (0.73 to 1.29) 130 (19.6) 1.41 (1.05 to 1.89)
49L1 115 (14.3) 115 (12.8) 0.96 (0.71 to 1.3) 114 (17.2) 1.47 (1.07 to 2.00)
75L1 74 (9.2) 78 (8.7) 1.02 (0.71 to 1.46) 81 (12.2) 1.68 (1.16 to 2.43)
76L1 45 (5.6) 44 (4.9) 0.95 (0.60 to 1.5) 50 (7.5) 1.74 (1.11 to 2.73)
β4 (92L1) 54 (6.7) 60 (6.7) 1.05 (0.70 to 1.58) 72 (10.9) 1.91 (1.28 to 2.86)
β5 (96L1) 67 (8.3) 73 (8.1) 1.03 (0.71 to 1.49) 88 (13.3) 2.03 (1.40 to 2.93)
*Adjusted for age, sex, level of education, cigarette smoking status one year before reference date (for squamous cell carcinoma only), skin
sensitivity as measured by skin reaction after one hour of sun exposure first time in summer, and number of lifetime painful sunburns.
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Sources used to identify controls—driver’s licence
and Medicare enrolment records—provide nearly
complete coverage of the study population.
23 Further-
more, we did not identify appreciable differences with
respect to age, sex, or urban versus rural residence
between people who were eligible and those who ulti-
matelyparticipated(datanotshown).Importantly,our
population based design is less susceptible to selection
bias than are the clinic or hospital based studies com-
prising much of the skin cancer literature and is more
representative of the general population than are spe-
cialised cohorts (such as organ transplant recipients).
Even so, the possibility of selection bias due to non-
participation can never be excluded; nor can we fully
exclude the possibility of residual confounding. Addi-
tionally,the studyisbasedona US,almostexclusively
white, population. Thus, generalisability to other,
especially non-white, populations is uncertain.
Our study took advantage of recent technologies to
measure antibodies to a wide range of cutaneous
human papillomavirus types. Our finding of a trend
of increase in risk of squamous cell carcinoma with
increasing numbers of β human papillomavirus types
supports a possible causative role of genus β human
papillomaviruses in squamous cell carcinoma.Further
proof of principle of our hypothesis was the greater
magnitude of risk among people exposed to immuno-
suppressive drugs (systemic glucocorticoids), as
expected on the basis of data from other groups of
immunosuppressed patients, albeit with limited statis-
ticalprecision.Importantly,wedidnotfindanassocia-
tionbetweenhumanpapillomavirusseropositivityand
immunosuppressive drug use in our control partici-
pants, suggesting that our observations were not sim-
ply a reflection of immune suppression.
By design, blood samples were collected after the
diagnosis of the case. The onset of skin cancer itself
might thus have resulted in increased susceptibility to
infection or immune response to human papilloma-
viruses. If these effects existed, they must have differen-
tially affected patients with basal cell carcinoma and
squamous cell carcinoma, as we found associations
only with squamous cell carcinoma. Additionally, they
wouldhaveneededtobespecifictoβhumanpapilloma-
viruses and not other human papillomavirus types, as
skin cancers have not been previously related to α or
mucosal human papillomaviruses.
6 Antibodies to
human papillomaviruses generally seem to be long
lived. In particular, persistence of human papilloma-
virus antibodies has been shown for high risk types (for
example, HPV 16/18);however, limited published data
exist on persistence of cutaneous human papilloma-
viruses.Toinvestigate whether seropositivitywasa con-
sequence of the squamous cell tumour (and not the
reverse), we analysed sera from 85 patients before and
after diagnosis by using archival samples from a skin
cancer prevention trial comprising patients with non-
melanocytic skin cancer followed for three to six years
for the occurrence of new malignancies.
24 We found
only one seroconversion out of the 16 who were nega-
tive for βhuman papillomavirus antibodies before diag-
nosis (that is, one person had a positive serology result
subsequent to a diagnosis of squamous cell carcinoma).
On the whole, it thus seems unlikely that our observa-
tionswere due simplyto higher antibodytitresresulting
from disease onset.
The analysis reported here was limited to a compre-
hensive assessment of only genus β human papilloma-
viruses. Other types, suchas γhuman papillomaviruses,
are found in non-melanoma skin cancers and are asso-
ciated with risk of squamous cell carcinoma.
11 Further
Table 3 |Risk of squamous cell carcinoma stratified by β human papillomavirus seropositivity
Risk factor
Seronegative
(No case/control)
Seropositive
(No case/control)
Strataspecificoddsratio
(95% CI)*
Skin sensitivity†:
Tan without sunburn 32/77 36/77 1.19 (0.66 to 2.14)
Mild sunburn with some tanning 141/219 154/189 1.22 (0.90 to 1.65)
Painful sunburn with peeling 111/114 120/84 1.46 (0.99 to 2.15)
Severe sunburn with blistering 26/24 40/19 1.85 (0.84 to 4.07)
Skin sensitivity:
Tan without sunburn/mild sunburn with some tanning 173/296 190/266 1.19 (0.91 to 1.56)
Painful sunburn with peeling/severe sunburn with blistering 137/138 160/103 1.54 (1.09 to 2.18)
No of lifetime painful sunburns:
None 82/142 87/114 1.31 (0.88 to 1.95)
1-2 61/127 78/104 1.45 (0.95 to 2.24)
3-9 43/62 48/52 1.32 (0.75 to 2.29)
≥10 121/100 132/95 1.17 (0.80 to 1.71)
Oral glucocorticoids:
No 272/400 295/336 1.23 (0.97 to 1.55)
Yes 23/25 36/18 3.21 (1.22 to 8.44)
*Stratum specific odds ratio for β human papillomavirus positivity; adjusted for age and sex for skin sensitivity and number of lifetime painful
sunburns; additionally adjusted for level of education, cigarette smoking status at one year before the reference date, skin sensitivity, and numbero f
lifetime painful sunburns for oral glucocorticoids.
†Defined as reaction to one hour of sun exposure first time in summer.
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virusesisthuswarranted,asareadequatelypoweredstu-
dies to determine the risk relations for people using
commonly prescribed immunosuppressive agents such
as glucocorticoids.
Comparison with other studies
Although an association between seropositivity to β
human papillomaviruses and risk of squamous cell car-
cinoma has been observed repeatedly,
4-11 data remain
inconsistent as to the species or types responsible. This
maybedueinparttotherelativelysmallstudysizesand
the narrowrangeofhumanpapillomavirustypestested
inpreviouswork.AclinicbasedstudyfromtheNether-
lands(161squamouscellcarcinomacasesand386con-
trols) tested six β human papillomaviruses (HPV 5, 8,
15,20,24,and38)andfoundelevatedrisksofsquamous
cell carcinoma for all but human papillomavirus 24,
with limited statistical precision.
5 Several smaller der-
matology clinic based investigations (with fewer than
100 cases of squamous cell carcinoma) found increased
odds ratios for squamous cell carcinoma in relation to
human papillomavirus 8.
4578 One of these also evalu-
atedhumanpapillomavirus15,36,and23andfoundan
oddsratioforsquamouscellcarcinomaofroughlythree
related to human papillomavirus 36.
7 Ar e c e n tc l i n i c
basedstudyfromSweden(72squamouscellcarcinoma
cases and 121 controls) found a similar prevalence of
humanpapillomavirusantibodiesinsquamouscellcar-
cinoma cases and controls but a higher prevalence
among squamous cell carcinoma cases than basal cell
carcinoma cases.
25 However, controls comprised surgi-
caldermatologypatientsinwhomconditionsassociated
with human papillomavirus infection might be over-
represented. A small nested case-control study of squa-
mous cell carcinoma from the United Kingdom (39
squamous cell carcinoma cases and 80 controls) found
nodifferencesinprevalenceofβhumanpapillomavirus
antibodies between cases and controls but slightly
higher rates among the 15prevalentsquamous cellcar-
cinoma cases than among the 39 incident cases.
26 In
addition to the small study size, case ascertainment
wasprobablyincompleteowingtorelianceontheregio-
nal cancer registry in this study.
As mentioned, the risk of squamous cell carcinoma
inourstudyseemedtobemoredependentonthenum-
ber of β types positive than on the specific type. Pre-
sence of multiple human papillomaviruses occurs
more commonly in skin tumours of transplant recipi-
ents than in the general population (reviewed in Nindl
et al
27), and in at least one other study a higher propor-
tion of squamous cell carcinoma cases than controls
wereseropositiveformorethanonehumanpapilloma-
virus type.
10 Infection with multiple types may lead to
enhancedviralreplicationorviralcapsidload,andthis
inturncouldenhanceriskofsquamouscellcarcinoma;
however, the mechanistic basis for this observation
needs to be explored further.
Skin cancers from patients with epidermodysplasia
verruciformis, who have suppressed cell mediated
immunity, contain β human papillomavirus DNA.
Organ transplant recipients who receive immunosup-
pressive drugs to prevent allograft rejection similarly
have an excess of keratinocyte tumours with human
papillomavirus DNA.
28 Previously, we and others
have reported an enhanced risk of squamous cell car-
cinoma associated with prolonged use of glucocorti-
coids for reasons other than organ transplantation
and hypothesised that people taking these drugs
might also be at risk of human papillomavirus related
squamous cellcarcinomas.
2930 As mentioned,our data
support this hypothesis and suggest that the known
association between the human papillomavirus and
occurrence of skin cancer in the presence of immuno-
suppressionextendstodrugsmorecommonlyusedby
the general population.
In vitro experiments indicate that the E6 protein of
several β human papillomaviruses inhibits apoptosis
induced by ultraviolet light through Bak
degradation.
31 Our findings provide some evidence
of an interaction between exposure to ultraviolet light
and human papillomavirus related risk of squamous
cellcarcinoma.Oddsratioswerehigheramongpeople
withcharacteristics indicative ofa higherdose ofultra-
violet light (sun sensitive phenotype) and to some
extent with histological evidence of actinic keratoses.
In contrast, we found no differences according to his-
tory of severe sunburn or stratified by tumours at
chronically sun exposed sites compared with other
sites. Nevertheless, ultraviolet light is a ubiquitous
exposure and presents measurement challenges for
epidemiological study.
32 Therefore, absence of any
detectable interactions would not necessarily preclude
ultraviolet light’s involvement in human papilloma-
virus induced skin cancers.
Conclusions and implications
An emerging body of evidence suggests a role of
human papillomavirus in the occurrence of squamous
cell carcinomas of the skin in the general population.
Our findings substantiate previous observations and
provide additional evidence for increasing risk with
WHAT IS ALREADY KNOWN ON THIS TOPIC
Genusβhumanpapillomavirusesareassociatedwithoccurrenceofskincanceramongorgan
transplant recipients and people with epidermodysplasia verruciformis
Epidemiologicaldatasuggestapossibleassociationinsquamouscellcarcinomasoftheskin
in the general population, but with study limitations
WHAT THIS STUDY ADDS
In a large population based case-control study, a wide range of genus β human
papillomavirus types were related to risk of squamous cell carcinoma but not basal cell
carcinoma
A trend existed inrisk ofsquamouscellcarcinoma inrelation tothe numberof genus β types
to which a person tested positive
The association was stronger among people who reported a history of prolonged
glucocorticoid use, although statistical precision was limited
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BMJ | ONLINE FIRST | bmj.com page 7 of 9greater numbers of β type infections rather than a
model in which risk is associated with either a single
human papillomavirus type or group of types. The
plausibility of our results was reinforced by a higher
magnitude of risk among users of immunosuppressive
drugs, although with limited statistical power. Further
mechanistic studies, along with prospective epidemio-
logical data, could help to elucidate the natural history
and timing of β human papillomavirus infection in the
pathogenesis of squamous cell carcinoma. Given the
widespread and growing occurrence of these malig-
nancies, our results raise the possibility of reducing
the health and economic burden of these cancers
through prevention or treatment of human papilloma-
virus infection.
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